Creative Antibiotics Sweden AB - Product Pipeline Review - 2012

Creative Antibiotics Sweden AB - Product Pipeline Review - 2012

Dec 2012 Global Markets Direct Antibiotics23 Pages Price :
$ 1500

 

Global Market Directs pharmaceuticals report, Creative Antibiotics Sweden AB Product Pipeline Review 2012 provides data on the Creative Antibiotics Sweden ABs research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Creative Antibiotics Sweden ABs corporate website, SEC filings, investor presentations and featured press releases, both from Creative Antibiotics Sweden AB and industry-specific third party sources, put together by Global Markets Directs team. 

 

Scope

 

  • Creative Antibiotics Sweden AB Brief Creative Antibiotics Sweden AB overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Creative Antibiotics Sweden AB human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Creative Antibiotics Sweden AB with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Creative Antibiotics Sweden ABs pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Evaluate Creative Antibiotics Sweden ABs strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Creative Antibiotics Sweden AB in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Creative Antibiotics Sweden ABs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Creative Antibiotics Sweden AB. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Creative Antibiotics Sweden AB and identify potential opportunities in those areas.

Table of Contents


Table of Contents 2
List of Tables 3
List of Figures 3
Creative Antibiotics Sweden AB Snapshot 4
Creative Antibiotics Sweden AB Overview 4
Key Information 4
Key Facts 4
Creative Antibiotics Sweden AB - Research and Development Overview 5
Key Therapeutic Areas 5
Creative Antibiotics Sweden AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Creative Antibiotics Sweden AB - Pipeline Products Glance 9
Creative Antibiotics Sweden AB - Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Creative Antibiotics Sweden AB - Drug Profiles 10
INP-1750 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
INP-1855 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Creative Antibiotics Sweden AB - Pipeline Products by Route of Administration 13
Creative Antibiotics Sweden AB - Discontinued Pipeline Products 14
Discontinued Pipeline Product Profiles 14
INP-341 14
Creative Antibiotics Sweden AB - Locations And Subsidiaries 15
Head Office 15
Financial Deals Landscape 16
Creative Antibiotics Sweden AB, Deals Summary 16
Creative Antibiotics Sweden AB, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Affibody Enters Into Co-Development Agreement With Creative Antibiotics 17
Creative Antibiotics Enters Into Co-Development Agreement With Albany Molecular Research 18
Syngene International Enters Into Collaboration With Innate Pharma 19
Equity Offering 20
Creative Antibiotics Completes Rights Issue Of $6.1 Million 20
 

Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Table


Creative Antibiotics Sweden AB, Key Information 4
Creative Antibiotics Sweden AB, Key Facts 4
Creative Antibiotics Sweden AB - Pipeline by Indication, 2012 6
Creative Antibiotics Sweden AB - Pipeline by Stage of Development, 2012 7
Creative Antibiotics Sweden AB - Monotherapy Products in Pipeline, 2012 8
Creative Antibiotics Sweden AB - Pre-Clinical, 2012 9
Creative Antibiotics Sweden AB - Pipeline By Route of Administration, 2012 13
Creative Antibiotics Sweden AB - Discontinued Pipeline Products, 2012 14
Creative Antibiotics Sweden AB, Deals Summary 16
Affibody Enters Into Co-Development Agreement With Creative Antibiotics 17
Creative Antibiotics Enters Into Co-Development Agreement With Albany Molecular Research 18
Syngene International Enters Into Collaboration With Innate Pharma 19
Creative Antibiotics Completes Rights Issue Of $6.1 Million 20

List of Chart


Creative Antibiotics Sweden AB - Pipeline by Indication, 2012 6
Creative Antibiotics Sweden AB - Pipeline by Stage of Development, 2012 7
Creative Antibiotics Sweden AB - Monotherapy Products in Pipeline, 2012 8

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 1500
$ 3000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top